880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial.
Saved in:
| Title: | 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial. |
|---|---|
| Authors: | Fuereder, T.1 (AUTHOR), Klinghammer, K.2 (AUTHOR), Hahn, D.A.3 (AUTHOR), Grünberger, B.4 (AUTHOR), Melchardt, T.5 (AUTHOR), Greil, R.5 (AUTHOR), Kocher, F.6 (AUTHOR), Gamerith, G.6 (AUTHOR), Wagner, C.1 (AUTHOR), Berchtold, L.1 (AUTHOR), Burian, M.7 (AUTHOR), Strobl, A.7 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS629-S629. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.941 |
